Note: Javascript is disabled or is not supported by your browser. For this reason, some items on this page will be unavailable. For more information about this message, please visit this page: About CDC.gov.

*S, susceptible to trimethoprim/sulfamethoxazole; in, inpatient; out, outpatient; CGA, clonal group A; R, resistant to trimethoprim/sulfamethoxazole; NK, not known.
†A list of the 32 centers is provided in the Technical Appendix. Note that 2 centers were located in Minneapolis.
‡<18 y of age.

*S, susceptible to trimethoprim/sulfamethoxazole; in, inpatient; out, outpatient; CGA, clonal group A; R, resistant to trimethoprim/sulfamethoxazole; NK, not known.
†A list of the 32 centers is provided in the Technical Appendix. Note that 2 centers were located in Minneapolis.
‡<18 y of age.

*S, susceptible to trimethoprim/sulfamethoxazole; in, inpatient; out, outpatient; CGA, clonal group A; R, resistant to trimethoprim/sulfamethoxazole; NK, not known.
†A list of the 32 centers is provided in the Technical Appendix. Note that 2 centers were located in Minneapolis.
‡<18 y of age.

1Investigators who contributed data are listed at the end of this article.

The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.